FDA authorizes second COVID antiviral pill, from Merck, if no alternatives available
CBSN
The Food and Drug Administration announced Thursday it had authorized molnupiravir, a drug produced by Merck and Ridgeback Biotherapeutics, to treat some American adults with COVID-19 who are at risk of severe disease when no other options are available. The pills are meant to be started within five days of developing the first symptoms.
"Molnupiravir is limited to situations where other FDA-authorized treatments for COVID-19 are inaccessible or are not clinically appropriate and will be a useful treatment option for some patients with COVID-19 at high risk of hospitalization or death," said the FDA's Dr. Patrizia Cavazzoni.
The agency's move marks the second emergency authorization for an antiviral pill to treat COVID-19 in as many days, after the FDA greenlighted Pfizer's Paxlovid on Wednesday. It comes ahead of a feared surge that could overwhelm hospitals as the Omicron variant rapidly spreads.

NASA announced ambitious long-range plans Tuesday to spend $20 billion over the next seven years to build a moon base near the lunar south pole featuring habitats, pressurized rovers and nuclear power systems. The announcement came just over a week before the planned launch of NASA's Artemis II around-the-moon mission. In:

The Trump administration deployed ICE and other Homeland Security agents to 14 of the nation's airports on Monday to help shuttle passengers through overcrowded TSA checkpoints. In one airport, the security line wait-time was up to six hours. Nicole Sganga and Kaia Hubbard contributed to this report. In:











